Lipid metabolism disorders within chronic kidney disease in association with metabolic syndrome

Abstract


The distribution and predictors of chronic kidney disease associated with metabolic syndrome among outpatients investigated and treated in policlinic № 30 (Petrograd region, St. Petersburg) were studied. 1800 patients with cardiovascular pathology were investigated, among them 380 patients (205 or 53,9% females and 175 or 46,1 % males) with metabolic syndrome and microalbuminuria were selected. The middle age of the patients was 59,2±3,6 (43+73) years, arterial hypertension lasted 12,0+ 4,5 years. The chronic kidney disease was diagnosed according to decrease of glomerular filtration rate and microalbuminuria. The distribution of metabolic syndrome with microalbuminuria among all patients studied was 21,1%. In patients with metabolic syndrome and microalbuminuria, a level of lipid metabolism disorders was shown to grow higher and blood pressure was increased in accordance with reduction of kidney function, that elevated risk of cardiovascular complications.

Full Text

Restricted Access

About the authors

T A Tarakanovskaya

Military Medical Academy, St. Petersburg


I A Yunusov

Military Medical Academy, St. Petersburg


References

  1. Мухин Н.А., Моисеев B.C. Пропедевтика внутренних болезней. М., 2002.
  2. Рентц Дун Б., Андерсон Ш., Бреннер Б. Гемодинамические основы прогрессирования почечных болезней // Современная нефрология / Матер. II Междунар. нефрол. семинара. М., 1997. С. 162-172.
  3. Смирнов А.В., Есаян A.M., Каюков И.Г. Хроническая болезнь почек: на пути к единству представлений // Нефрология. 2002. № 6. С. 11-17.
  4. Смирнов А.В., Каюков И.Г., Есаян A.M. и др. Превентивный подход в современной нефрологии // Нефрология. 2004. Т. 8. № 3. С. 7-14.
  5. Смирнов А.В., Добронравов В.А., Каюков И.Г. Кардиоренальный континуум: патогенетические основы превентивной нефрологии // Нефрология. 2005. №9. С. 7-15.
  6. Смирнов А.В., Добронравов В.А., Каюков И.Г, Есаян A.M. Хроническая болезнь почек: дальнейшее развитие концепции и классификации // Нефрология. 2007. № 11. С. 7-17.
  7. Смирнов А.В. Дислипопротеидемии и проблемы нефропротекции // Нефрология. 2002. № 6. С. 8-14.
  8. A science advisory from the American Heart Association Kidney and Cardiovascular Disease Council//Circulation. 2006. Vol. 114. P. 1083-1087.
  9. Abbate M., Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? // J. Am. Soc. Nephrol. 2006. Vol. 17. № 11. P. 2974-2984.
  10. Bakris G.L., Weir M.R., Secic M. et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression // Kidney Int. 2004. Vol. 6. P. 1991-2002.
  11. Brantsma A.H., Bakker S.J., Hillege H.L. et al. Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes // Diabetes Care. 2005. Vol. 10. P. 2525-2530.
  12. Eddy A.A., Neilson E.G. Chronic kidney disease progression // J. Am. Soc. Nephrol. 2006. Vol. 11. P. 29642966.
  13. Eddy A.A. Progression in chronic kidney disease // Adv. Chronic Kidney Dis. 2005. Vol. 12. P. 353-365
  14. Forman J.P, Brenner B.M. «Hypertension» and «microalbuminuria»: The bell tolls for thee // Kidney Int. 2006. Vol. 69. P. 22-28.
  15. Hunsicker L.G., Adler S„ Caggiula A. et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study // Kidney Int. 1997. Vol. 51. P. 1908-1919.
  16. Jones C, Roderick P., Harris $,, Rogerson M. Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease // Nephrol. Dial. Transplant. 2006. Vol. 21. P. 2133-2143.
  17. Klausen K.P., Scharling H., Jensen G., Jensen J.S. New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death // Hypertension. 2005. Vol. 46. P. 33-37.
  18. Levey A.S., Eckardt K.U., Tsukamoto Y. et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) // Kidney Int. 2005. Vol. 67. P. 2089-2100.
  19. Locatelli F„ Del Vecchio L., D'Amico M., Andrulli S. Is it the agent or the blood pressure level that matters for renal protection in chronic nephropathies? // J. Am. Soc. Nephrol. 2002. Vol. 3. P. 196-201.
  20. MacKinnon M., Shurraw S., Akbari A. et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data // Kidney Dis. 2006. Vol. 48. P. 8-20.
  21. Mann J.F., Gerstein H.C., Yi Q.L., Franke J. et al. HOPE Investigators: Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: Results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study // Am. J. Kidney Dis. 2003. Vol. 42. P. 936-942.
  22. Meisinger C, Doring A., Lowel H. KORA Study Group. Chronic kidney disease and risk of incident myocardial infarction and allca,use and cardiovascular disease mortality in middleaged men and women from the general population // Eur. Heart. J. 2006. Vol. 27. P. 1245-1250.
  23. Metcalfe W. How does early chronic kidney disease progress? A background paper prepared for the UK Consensus Conference on early chronic kidney disease // Nephrol. Dial. Transplant. 2007. Vol. 22 (Suppl. 9). P. 26-30.
  24. National Kidney Foundation KD: Clinical practice guidelines for chronic Kidney disease: Evaluation, classification and stratification //Am. J. Kidney Dis. 2002. Vol. 39 (Suppl. 1). P. S1-S266.
  25. Rahman M., Pressel S., Davis B.R. et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate // Ann. Intern. Med. 2006. Vol. 144. P. 172-180.
  26. Remuzzi G., Ruggenenti P., Benigni A. Understanding the nature of renal disease progression // Kidney Int. 1997. Vol. 51. P. 2-15.
  27. Rossing P., Hommel E., Smidt U, Parving H. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment // Diabetologia. 1994. Vol. 37. P. 511-516.
  28. Schaeffher E.S., Kurth Т., Curhan G.C. et al. Choles terol and the risk of renal dysfunction in apparently healthy men // J. Am. Soc. Nephrol. 2003. Vol. 14. P. 2084-2091.
  29. Schmieder R.E., Schrader J., Zidek W. et al. Lowgrade albuminuria and cardiovascular risk: what is the evidence? // Clin. Res. Cardiol. 2007. Vol. 96. P. 247-. 257.
  30. Tonelli M., Моуё L., Sacks F.M. et al. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease // J. Am. Soc. Nephrol. 2003. Vol. 14. P. 1605-1613.
  31. Vanholder R., Massy Z., Argiles A. et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality // Nephrol. Dial. Transplant. 2005. Vol. 20. P. 1048-1056.
  32. Verhave J.C., Hillege H.L., Burgerhof J.G. et al. PRE-VEND Study Group: The association between atherosclerotic risk factors and renal function in the general population // Kidney Int. 2005. Vol. 67. P. 19671973.
  33. Yu H.T. Progression of chronic renal failure //Arch. Intern. Med. 2003. Vol. 163. P. 1417-1429.

Statistics

Views

Abstract - 88

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2009 Tarakanovskaya T.A., Yunusov I.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies